| Molecule | Cat. No. | Product Name | 種 | Host | Structure | Purity | Activity | Size&Price |
|---|---|---|---|---|---|---|---|---|
| Complement C5a | HOT C5A-H5116 | Human Complement C5a Protein, Tag Free | Human | E. coli | ![]() | SDS-PAGE | $245.00 50ug | |
| Complement C5a | HOT C5A-H51H9 | Human Complement C5a Protein, His Tag | Human | E. coli | ![]() | SDS-PAGE | $245.00 50ug | |
| Complement C5a | HOT C5A-C5118 | Cynomolgus Complement C5a Protein, Tag Free | Cynomolgus | E. coli | ![]() | SDS-PAGE | $390.00 100ug | |
| Complement C5a | HOT C5A-C51H9 | Cynomolgus Complement C5a Protein, His Tag | Cynomolgus | E. coli | ![]() | SDS-PAGE | $245.00 50ug | |
| Complement C5a | HOT C5A-M51H4 | Mouse Complement C5a Protein, His Tag | Mouse | E. coli | ![]() | SDS-PAGE | $360.00 100ug | |
| Complement C5a | Human Complement C5a Protein, Fc Tag (MALS verified) | Human | HEK293 | ![]() | MALSSDS-PAGE | $360.00 100ug |
| 英語名 | 研究コード | 研究開発ステージ | 会社 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|
| BDB-001 | BDB-001; BDB001; BDB 001; BDB-1 | Phase 3 Clinical | Staidson(Beijing) Biopharmaceuticals Co Ltd | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Coronavirus Disease 2019 (COVID-19); Hidradenitis Suppurativa; Vasculitis | 詳細 |
| STSA-1002 | STSA-1002; STSA1002 | Phase 3 Clinical | Staidson(Beijing) Biopharmaceuticals Co Ltd | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Coronavirus Disease 2019 (COVID-19); Respiratory Distress Syndrome, Adult | 詳細 |
| 英語名 | 研究コード | 研究開発ステージ | 会社 | オリジナル製品名 | 最初に承認をした国 | 最初の適応症 | 最初に承認を受けた会社 | 承認された日付 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|---|---|---|---|---|
| Vilobelimab | IFX-1; CaCP-29 | Approved | Inflarx Nv | Gohibic | EU | Respiratory Distress Syndrome, Adult | Inflarx Nv, Inflarx Gmbh | 2025-01-13 | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Carcinoma, Squamous Cell; Coronavirus Disease 2019 (COVID-19); Drug-Related Side Effects and Adverse Reactions; Granulomatosis with Polyangiitis; Hidradenitis Suppurativa; Microscopic Polyangiitis; Pyoderma Gangrenosum; Respiratory Distress Syndrome, Adult; Sepsis; Shock, Septic; Systemic Inflammatory Response Syndrome | 詳細 |
